Search Results 681-690 of 14676 for anti-TNF drugs

  1. Urology Clinical Trials - Medical Professionals

    Clinical Trials · A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for ...

  2. Nivolumab (Intravenous Route) Description and Brand Names - Mayo Clinic

    Nivolumab injection is also used with chemo medicines containing platinum before having surgery for non-small cell lung cancer (NSCLC).

  3. Thalidomide (Oral Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  4. Terbinafine (Oral Route) Description and Brand Names - Mayo Clinic

    Terbinafine belongs to the group of medicines called antifungals. It is used to treat fungus infections of the scalp, body, groin (jock itch), feet (athlete's ...

  5. Antihemophilic Factor (Intravenous Route) Precautions - Mayo Clinic

    Precautions. Drug information provided by: Merative, Micromedex®. It is very important that your doctor check you or your child closely while you are ...

  6. Trastuzumab-Strf (Intravenous Route) Description and Brand Names - Mayo Clinic

    Descriptions. Trastuzumab-strf injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or ...

  7. Therapeutic Drug Monitoring of Pembrolizumab and Nivolumab to Determine Dosages for Cancer Treatment - Mayo Clinic

    About this study. Drug monitoring of Pembrolizumaband Nivolumab for determining the pharmacokinetic (PK) profile of these medications and to provide ...

  8. Milnacipran (Oral Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  9. A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma - Mayo Clinic

    About this study. The primary objectives of this study are to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib + ...

  10. Targeting VEGF-Independent Proangiogenic Pathways in Anti-VEGF Refractory Renal Cell Cancer - Tumor Angiogenesis and Vascular Biology Laboratory - Mayo Clinic Research

    Mukhopadhyay's lab is developing novel treatment strategies to target these pathways for refractory and highly aggressive tumor types and for sarcomatoid renal ...